Previous Next

2024-03-08

Batoclimab in myasthenia gravis

Neurology

In this multicenter randomized clinical trial conducted from September 15, 2021 to June 29, 2022 at 27 centers in China, investigators evaluated the efficacy and safety profile of batoclimab, an anti-IgG1 monoclonal antibody, in myasthenia gravis. A total of 178 adult patients with myasthenia gravis were screened, 132 were randomly assigned, 131 tested positive for antibodies and 1 tested negative for antibodies. Treatment cycles included 6 weekly subcutaneous injections of batoclimab 680 mg or placebo. Differences between patient groups were significant from the second week of treatment, with an advantage for the batoclimab group.

Source(s) :
Chong Yan et al. Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial. JAMA Neurol. 2024 Mar 4. ;

Last press reviews


HIV and Dual Therapy: a promising step towards maintaining viral suppression

The introduction of dual therapies in HIV treatment marks a significant ad...

L-arginine: a promising advance for reducing inflammatory and cardiac markers after coronary artery bypass surgery

Coronary artery bypass grafting (CABG) is a critical procedure to restore...

HIV and Innate Immunity: How Early Responses Shape the Evolution of Viral Reservoirs

HIV infection remains a significant challenge in the field of infectious d...